With Nevisense, dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2 percent to 91.1 percent.

SciBase’s Nevisense test provides benefit over standard of care visual and dermoscopic evaluation for biopsy decisions, according to a study in Melanoma Research.

The study included 231 US dermatologists making a total of 33.957 biopsy decisions. The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result. With Nevisense, dermatologists identified more melanomas for biopsy; their sensitivity increasing from 85.2 percent to 91.1 percent.

"The overall findings from this study demonstrate that the integration of electrical impedance spectroscopy technology into pigmented skin lesiion biopsy decisions has the potential to significantly improve the accuracy of lesion selection for biopsy beyond clinical and dermoscopic evaluation alone," says stidy suthor  Darrell Rigel, MD, a dermatologisy at the Icahn School of Medicine at Mount Sinai in New York City. 

"This is a very important study and result for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense compared to visual methods that are today considered the standard of care. As expected, the study showed that dermoscopy improved decision making over naked eye assessment, but more importantly it showed that using Nevisense further improved clinician performance by at least as much again. Adding Nevisense clearly resulted in the best clinical management decisions. This is one of several publications that shows that Nevisense has a significant role in the challenging process for clinicians to identify malignancies," adds Simon Grant, CEO of SciBase.